Yuelong Jiang
Key Laboratory Of Xiamen For Diagnosis And Treatment Of Hematological Malignancy
Xiamen, China
Xiamen, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
Rewiring NADH Metabolism Through NQO1-Mediated Redox Cycling for Targeted Follicular Lymphoma Therapy.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: March 21, 2026
Combination of HDAC inhibitor and PI3K inhibitor suppresses autophagy and induces apoptosis via cytoplasmic IκBα stabilization in p53-mutant diffuse large B-cell lymphoma.
Journal: Cell death discovery
Published: May 21, 2025
DGKα inhibition enhances the antitumor effect of chiauranib on transformed follicular lymphoma.
Journal: Annals of hematology
Published: March 18, 2025
Venetoclax confers synthetic lethality to chidamide in preclinical models with transformed follicular lymphoma.
Journal: Clinical epigenetics
Published: December 11, 2024
Chiglitazar diminishes the warburg effect through PPARγ/mTOR/PKM2 and increases the sensitivity of imatinib in chronic myeloid leukemia.
Journal: Experimental hematology & oncology
Published: September 03, 2024
Effect of prior lenalidomide or daratumumab exposure on hematopoietic stem cell collection and reconstitution in multiple myeloma.
Journal: Annals of hematology
Published: January 02, 2024
Ritanserin suppresses acute myeloid leukemia by inhibiting DGKα to downregulate phospholipase D and the Jak-Stat/MAPK pathway.
Journal: Discover oncology
Published: April 14, 2023
Anlotinib suppresses the DNA damage response by disrupting SETD1A and inducing p53-dependent apoptosis in Transformed Follicular Lymphoma.
Journal: International journal of medical sciences
Published: April 04, 2023
Preclinical Studies of Chiauranib Show It Inhibits Transformed Follicular Lymphoma through the VEGFR2/ERK/STAT3 Signaling Pathway.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: November 15, 2022
Orelabrutinib and venetoclax synergistically induce cell death in double-hit lymphoma by interfering with the crosstalk between the PI3K/AKT and p38/MAPK signaling.
Journal: Journal of cancer research and clinical oncology
Published: September 21, 2022
Last Updated: 09/26/2026